This is what analysts have to say about Curis, Inc. (NASDAQ:CRIS) after last week.

April 17, 2018 - By Adrian Erickson

Curis, Inc. (NASDAQ:CRIS) LogoInvestors sentiment increased to 1.59 in 2017 Q4. Its up 0.11, from 1.48 in 2017Q3. It improved, as 6 investors sold Curis, Inc. shares while 21 reduced holdings. 14 funds opened positions while 29 raised stakes. 75.55 million shares or 1.01% less from 76.32 million shares in 2017Q3 were reported.
92,600 are held by Janney Montgomery Scott Lc. Schwab Charles Investment Mngmt Incorporated has invested 0% in Curis, Inc. (NASDAQ:CRIS). Sg Americas Llc has 269,128 shares for 0% of their portfolio. Tower Rech Cap Limited Liability Company (Trc) stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Millennium Management Lc has 3.15 million shares. Perceptive Limited Liability Company accumulated 0.02% or 951,201 shares. Silvercrest Asset Mngmt Grp Limited reported 30,000 shares. State Street holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 1.88 million shares. Bnp Paribas Arbitrage Sa holds 35,793 shares or 0% of its portfolio. Voya Lc holds 0% in Curis, Inc. (NASDAQ:CRIS) or 59,413 shares. State Of Wisconsin Invest Board reported 86,000 shares. Jpmorgan Chase & Company reported 0% in Curis, Inc. (NASDAQ:CRIS). Manufacturers Life Insur The holds 0% in Curis, Inc. (NASDAQ:CRIS) or 29,192 shares. Bb&T Ltd Liability holds 0% or 96,522 shares in its portfolio. Credit Suisse Ag stated it has 47,453 shares or 0% of all its holdings.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 2 analysts covering Curis Inc (NASDAQ:CRIS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Curis Inc had 2 analyst reports since October 23, 2017 according to SRatingsIntel. Guggenheim initiated it with “Buy” rating and $7.0 target in Monday, October 23 report. Below is a list of Curis, Inc. (NASDAQ:CRIS) latest ratings and price target changes.

06/12/2017 Broker: Cowen & Co Rating: Buy
23/10/2017 Broker: Guggenheim Rating: Buy New Target: $7.0 Initiate

The stock increased 5.17% or $0.0312 during the last trading session, reaching $0.635. About 858,361 shares traded. Curis, Inc. (NASDAQ:CRIS) has declined 76.80% since April 17, 2017 and is downtrending. It has underperformed by 88.35% the S&P500.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $105.17 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Curis, Inc. (NASDAQ:CRIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: